CRVO
MCID: CNT016
MIFTS: 36

Central Retinal Vein Occlusion (CRVO) malady

Categories: Rare diseases, Cardiovascular diseases

Aliases & Classifications for Central Retinal Vein Occlusion

Aliases & Descriptions for Central Retinal Vein Occlusion:

Name: Central Retinal Vein Occlusion 12 56 52 14 69
Crvo 56

Characteristics:

Orphanet epidemiological data:

56
central retinal vein occlusion
Prevalence: 1-5/10000 (Europe); Age of onset: Adult,Elderly;

Classifications:



External Ids:

Disease Ontology 12 DOID:2450
ICD10 33 H34.81
ICD9CM 35 362.35
NCIt 47 C118859
SNOMED-CT 64 193378003 68478007
Orphanet 56 ORPHA411527
ICD10 via Orphanet 34 H34.8
UMLS 69 C0154841

Summaries for Central Retinal Vein Occlusion

MalaCards based summary : Central Retinal Vein Occlusion, also known as crvo, is related to retinitis and retinal vein occlusion. An important gene associated with Central Retinal Vein Occlusion is VEGFA (Vascular Endothelial Growth Factor A). The drugs Bevacizumab and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include retina, eye and endothelial.

Wikipedia : 71 The central retinal vein is the venous equivalent of the central retinal artery and, like that blood... more...

Related Diseases for Central Retinal Vein Occlusion

Diseases in the Retinal Vein Occlusion family:

Central Retinal Vein Occlusion

Diseases related to Central Retinal Vein Occlusion via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 100)
id Related Disease Score Top Affiliating Genes
1 retinitis 11.2
2 retinal vein occlusion 11.2
3 endotheliitis 10.4
4 chorioretinitis 10.4
5 hyperhomocysteinemia 10.3
6 neovascular glaucoma 10.3
7 choroiditis 10.2
8 retinal artery occlusion 10.2
9 retinal detachment 10.1
10 macular holes 10.1
11 neuropathy 10.1
12 leukemia 10.1
13 thrombotic thrombocytopenic purpura 10.1
14 protein s deficiency 10.1
15 thrombophilia 10.1
16 central retinal artery occlusion 10.1
17 cytomegalovirus retinitis 10.1
18 vasculitis 10.1
19 purpura 10.1
20 ischemic optic neuropathy 10.0
21 tuberculosis 10.0
22 multiple myeloma 10.0
23 retinal vasculitis 10.0
24 branch retinal artery occlusion 10.0
25 ischemia 10.0
26 myeloid leukemia 10.0
27 lupus erythematosus 9.9
28 open-angle glaucoma 9.9
29 rubeosis iridis 9.9
30 psoriasis 9.9
31 macroglobulinemia 9.9
32 ulcerative colitis 9.9
33 hepatitis c 9.9
34 iron deficiency anemia 9.9
35 pneumonia 9.9
36 thrombocytosis 9.9
37 hemolytic-uremic syndrome 9.9
38 deficiency anemia 9.9
39 colitis 9.9
40 cryoglobulinemia 9.9
41 pulmonary hypertension 9.9
42 thrombosis 9.9
43 crohn's disease 9.9
44 systemic lupus erythematosus 9.9
45 hepatitis 9.9
46 renal cell carcinoma 9.8
47 interstitial nephritis 9.8
48 posterior scleritis 9.8
49 cavernous sinus thrombosis 9.8
50 angiomatosis 9.8

Comorbidity relations with Central Retinal Vein Occlusion via Phenotypic Disease Network (PDN):


Hypertension, Essential

Graphical network of the top 20 diseases related to Central Retinal Vein Occlusion:



Diseases related to Central Retinal Vein Occlusion

Symptoms & Phenotypes for Central Retinal Vein Occlusion

Drugs & Therapeutics for Central Retinal Vein Occlusion

Drugs for Central Retinal Vein Occlusion (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 153)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216974-75-3
2
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 124-94-7 31307
3
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1 347396-82-1 459903
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
5
Verteporfin Approved, Investigational Phase 4 129497-78-5
6
Glucosamine Approved, Nutraceutical Phase 4 3416-24-8 439213
7 Endothelial Growth Factors Phase 4,Phase 3,Phase 1,Phase 2
8 Mitogens Phase 4,Phase 3,Phase 1,Phase 2
9 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
10 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
12 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
13 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
14 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
15 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
16 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
17 triamcinolone acetonide Phase 4,Phase 2,Phase 3,Phase 1
18 Triamcinolone diacetate Phase 4,Phase 2,Phase 3,Phase 1
19 Triamcinolone hexacetonide Phase 4,Phase 2,Phase 3,Phase 1
20 Antiemetics Phase 4,Phase 2,Phase 3,Phase 1
21 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1
22 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1
23 BB 1101 Phase 4,Phase 2,Phase 3,Phase 1
24 Dexamethasone 21-phosphate Phase 4,Phase 2,Phase 3,Phase 1
25 Dexamethasone acetate Phase 4,Phase 2,Phase 3,Phase 1 1177-87-3
26 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
27 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
28 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
29
protease inhibitors Phase 4,Phase 2,Phase 3,Phase 1
30 Antimetabolites Phase 4,Phase 3,Phase 2
31 Fibrinolytic Agents Phase 4,Phase 3,Phase 1
32 Hypolipidemic Agents Phase 4,Phase 3,Phase 2
33 Lipid Regulating Agents Phase 4,Phase 3,Phase 2
34 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
35
Lactitol Phase 4 585-86-4 3871
36 Mitomycins Phase 4
37 Anticoagulants Phase 4,Phase 3
38 Glucuronyl glucosamine glycan sulfate Phase 4
39 Hypoglycemic Agents Phase 4
40 Dermatologic Agents Phase 4,Phase 1,Phase 2
41 Photosensitizing Agents Phase 4
42 histidine Nutraceutical Phase 4
43
Betamethasone Approved, Vet_approved Phase 2, Phase 3 378-44-9 9782
44
Ephedrine Approved Phase 2, Phase 3 299-42-3 9294
45
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
46
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
47
Pseudoephedrine Approved Phase 2, Phase 3 90-82-4 7028
48
Ethanol Approved Phase 3 64-17-5 702
49
Eplerenone Approved Phase 2, Phase 3 107724-20-9 150310 443872
50
Spironolactone Approved Phase 2, Phase 3 1952-01-7, 52-01-7 5833

Interventional clinical trials:

(show top 50) (show all 216)
id Name Status NCT ID Phase
1 Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy Unknown status NCT01857544 Phase 4
2 Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO Unknown status NCT00566761 Phase 4
3 Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion Completed NCT01448018 Phase 4
4 NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions Completed NCT01870427 Phase 4
5 Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Completed NCT01710839 Phase 4
6 Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO Completed NCT01580020 Phase 4
7 Intraocular Bevacizumab (Avastin) for Rubeosis Iridis Completed NCT00557232 Phase 4
8 A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion Completed NCT01277302 Phase 4
9 Single Site, Masked, Randomized, Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion Completed NCT01085734 Phase 4
10 Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion Completed NCT00406107 Phase 4
11 Ranibizumab in Patients With Branch Retinal Vein Occlusion Completed NCT01027481 Phase 4
12 Dexamethasone-implant for the Treatment of RVO Completed NCT01767545 Phase 4
13 Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion Completed NCT01427751 Phase 4
14 A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion Completed NCT01903720 Phase 4
15 Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema. Completed NCT02140411 Phase 4
16 Morphological and Functional Retinal Changes Following Retinal Photocoagulation Completed NCT00682240 Phase 4
17 Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma Completed NCT01922154 Phase 4
18 Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO Recruiting NCT02800642 Phase 4
19 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion Recruiting NCT01827722 Phase 4
20 Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion Recruiting NCT02478515 Phase 4
21 Comparison of Retinal Oxygenation and Retinal Vessel Diameters in Healthy Subjects and Patients With Diabetic Retinopathy or Retinal Vein Occlusion Between DVA and Oxymap Recruiting NCT02521116 Phase 4
22 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema Recruiting NCT02684084 Phase 4
23 Retinal Sensitivity in BRVO After Anti-VEGF Therapy Recruiting NCT02527733 Phase 4
24 Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety Recruiting NCT02953938 Phase 4
25 Continuation of Previous Study to Gather More Data on Effect of Macugen on the Corneal Endothelium Recruiting NCT01573572 Phase 4
26 Cohort Study of the Clinical Course of Macular Diseases in Kagawa Recruiting NCT02321267 Phase 4
27 Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen Active, not recruiting NCT02274259 Phase 4
28 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO Active, not recruiting NCT02503540 Phase 4
29 Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision Active, not recruiting NCT01795209 Phase 4
30 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Not yet recruiting NCT02522897 Phase 4
31 Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept Not yet recruiting NCT03056079 Phase 4
32 Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab Not yet recruiting NCT03056092 Phase 4
33 Atorvastatin for the Treatment of Retinal Vein Occlusion Unknown status NCT00517257 Phase 3
34 Comparison of Intravitreal Ranibizumab and Macular Laser Photocoagulation for ME Following Branch Retinal Vein Occlusion (BRVO) Unknown status NCT01189526 Phase 3
35 Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO) Unknown status NCT01635803 Phase 2, Phase 3
36 Effect of Avastin in Juxtafoveal Telangiectasias Unknown status NCT00406380 Phase 3
37 Bevacizumab for Central Retinal Vein Occlusion Study Completed NCT00906685 Phase 3
38 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) Completed NCT00943072 Phase 3
39 Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) Completed NCT01976312 Phase 3
40 Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion Completed NCT01295112 Phase 2, Phase 3
41 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) Completed NCT01012973 Phase 3
42 Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion Completed NCT01535261 Phase 3
43 Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO) Completed NCT01396083 Phase 3
44 A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE) Completed NCT00485836 Phase 3
45 The ROVO Study: Radial Optic Neurotomy for CVO Completed NCT00532142 Phase 2, Phase 3
46 A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO Completed NCT00567697 Phase 3
47 Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion Completed NCT01377597 Phase 3
48 The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study Completed NCT00105027 Phase 3
49 Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion Completed NCT01198327 Phase 3
50 Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions Completed NCT00500045 Phase 2, Phase 3

Search NIH Clinical Center for Central Retinal Vein Occlusion

Genetic Tests for Central Retinal Vein Occlusion

Anatomical Context for Central Retinal Vein Occlusion

MalaCards organs/tissues related to Central Retinal Vein Occlusion:

39
Retina, Eye, Endothelial, Myeloid, Skin, Liver, Colon

Publications for Central Retinal Vein Occlusion

Articles related to Central Retinal Vein Occlusion:

(show top 50) (show all 639)
id Title Authors Year
1
Assessment of ischemia in acute central retinal vein occlusion from inner retinal reflectivity on spectral domain optical coherence tomography. ( 28053503 )
2017
2
Fernlike Maculopathy in a Patient With Central Retinal Vein Occlusion. ( 27281739 )
2016
3
Central Retinal Vein Occlusion and Paracentral Acute Middle Maculopathy Diagnosed With En Face Optical Coherence Tomography. ( 27631483 )
2016
4
MACULAR PERIVENOUS RETINAL WHITENING AND PRESUMED RETINO-CILIARY SPARING IN A RECURRENT CENTRAL RETINAL VEIN OCCLUSION ASSOCIATED WITH THE ANTIPHOSPHOLIPID SYNDROME AND CRYOGLOBULINEMIA. ( 27902540 )
2016
5
Optical Coherence Tomography Angiography in Central Retinal Vein Occlusion: Correlation Between the Foveal Avascular Zone and Visual Acuity. ( 27409478 )
2016
6
Spontaneous resolution of bilateral central retinal vein occlusion with cystoid macular oedema during pregnancy. ( 27879054 )
2016
7
Central retinal vein occlusion as the initial presentation in leptomeningeal carcinomatosis. ( 27146934 )
2016
8
Long-Term Functional and Anatomical Outcome of Radial Optic Neurotomy for Central Retinal Vein Occlusion. ( 27116505 )
2016
9
Central Retinal Artery Occlusion With Subsequent Central Retinal Vein Occlusion in Biopsy-Proven Giant Cell Arteritis. ( 27261946 )
2016
10
Systematic literature review of treatments for management of complications of ischemic central retinal vein occlusion. ( 27401800 )
2016
11
Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion. ( 27632214 )
2016
12
Correlation between optic nerve head circulation and visual function before and after anti-VEGF therapy for central retinal vein occlusion: prospective, interventional case series. ( 27044276 )
2016
13
Central Retinal Vein Occlusion Associated With Severe Vitamin D Deficiency. ( 27065380 )
2016
14
Topical Squalamine 0.2% and Intravitreal Ranibizumab 0.5 mg as Combination Therapy for Macular Edema Due to Branch and Central Retinal Vein Occlusion: An Open-Label, Randomized Study. ( 27759857 )
2016
15
SCORE2 Report 1: Techniques to Optimize Recruitment in Phase III Clinical Trials of Patients with Central Retinal Vein Occlusion. ( 27450625 )
2016
16
An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients. ( 27319943 )
2016
17
Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study. ( 27401726 )
2016
18
Vitamin D Deficiency in Patients with Central Retinal Vein Occlusion: A Case Control Study. ( 27348601 )
2016
19
ASSOCIATION BETWEEN RETINAL HEMORRHAGIC PATTERNS AND PERFUSION STATUS IN EYES WITH ACUTE CENTRAL RETINAL VEIN OCCLUSION. ( 27611056 )
2016
20
Predictors of short-term outcomes related to central subfield foveal thickness after intravitreal bevacizumab for macular edema due to central retinal vein occlusion. ( 26949616 )
2016
21
Response to: 'Comment on Central retinal vein occlusion: modifying current treatment protocols'. ( 27101756 )
2016
22
Frosted Branch Angiitis Secondary to Familial Mediterranean Fever Resembling Central Retinal Vein Occlusion. ( 28044118 )
2016
23
OUTER RETINAL LAYER CHANGES AFTER DEXAMETHASONE IMPLANT FOR CENTRAL RETINAL VEIN OCCLUSION. ( 28030428 )
2016
24
Accidental intralenticular dexamethasone intravitreal implant with the resolution of macular oedema in central retinal vein occlusion. ( 27125991 )
2016
25
Central Retinal Vein Occlusion Associated with Ulcerative Colitis. ( 27560849 )
2016
26
Individualized Ranibizumab Regimen Driven by Stabilization Criteria for Central Retinal Vein Occlusion: Twelve-Month Results of the CRYSTAL Study. ( 26896124 )
2016
27
Clinical Efficacy and Safety of Ranibizumab versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study. ( 27163237 )
2016
28
Bilateral Central Retinal Vein Occlusion as Presenting Feature of Chronic Myeloid Leukemia. ( 27555710 )
2016
29
EARLY CRT MONITORING USING TIME-DOMAIN OPTICAL COHERENCE TOMOGRAPHY DOES NOT ADD TO VISUAL ACUITY FOR PREDICTING VISUAL LOSS IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION TREATED WITH INTRAVITREAL RANIBIZUMAB: A Secondary Analysis of Trial Data. ( 27548351 )
2016
30
Hyperbaric oxygen for the treatment of the rare combination of central retinal vein occlusion and cilioretinal artery occlusion. ( 27044464 )
2016
31
Concomitant multiple myeloma spectrum diagnosis in a central retinal vein occlusion: a case report and review. ( 27079282 )
2016
32
A Case of Ocular Decompression Retinopathy Mimicking Central Retinal Vein Occlusion. ( 27478361 )
2016
33
BILATERAL CENTRAL RETINAL VEIN OCCLUSIONS IN A YOUNG PATIENT WITH A HISTORY OF EOSINOPHILIC PNEUMONIA AND THALAMIC STROKE. ( 28045864 )
2016
34
Retrospective, controlled observational case study of patients with central retinal vein occlusion and initially low visual acuity treated with an intravitreal dexamethasone implant. ( 27784291 )
2016
35
TECHNIQUE OF LASER CHORIORETINAL ANASTOMOSIS CREATION IN CENTRAL RETINAL VEIN OCCLUSION AND SUCCESS RATE WITH A NEW PHOTOCOAGULATOR SYSTEM. ( 26991650 )
2016
36
Central Retinal Vein Occlusion in a Childhood Optic Nerve Tumour. ( 27928381 )
2016
37
Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion. ( 27660163 )
2016
38
Central retinal vein occlusion concomitant with dengue fever. ( 27847619 )
2016
39
Comment on: 'Central retinal vein occlusion: modifying current treatment protocols'. ( 27101747 )
2016
40
Central retinal vein occlusion associated with high blood levels of lipoprotein (a).: Is lipoprotein (a) a reliable marker for identification of predisposed individuals? ( 28003785 )
2016
41
A Rare Cause of Unilateral Central Retinal Vein Occlusion in a Young Patient: Type III Mixed Cryoglobulinemia. ( 27418988 )
2016
42
Central retinal vein occlusion in an otherwise healthy child treated successfully with a single injection of bevacizumab. ( 26988773 )
2016
43
Radial optic neurotomy in treating central retinal vein occlusion: a Meta-analysis. ( 27366695 )
2016
44
Central retinal vein occlusion after plateletpheresis. ( 27264010 )
2016
45
Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion. ( 27769324 )
2016
46
Comparison of anti-vascular endothelial growth factors, laser treatments and a combination of the both for treatment of central retinal vein occlusion. ( 27158615 )
2016
47
Outcomes of Patients Initially Treated with Intravitreal Bevacizumab for Central Retinal Vein Occlusion: Long-Term Follow-Up. ( 27911131 )
2016
48
Necrotizing Fasciitis of the Periorbital Region Complicated by Combined Central Retinal Artery Occlusion, Central Retinal Vein Occlusion, and Posterior Ciliary Occlusion. ( 27556345 )
2016
49
Baseline Choroidal Thickness as a Predictor for Treatment Outcomes in Central Retinal Vein Occlusion. ( 27567889 )
2016
50
Optical coherence tomography angiography in paracentral acute middle maculopathy secondary to central retinal vein occlusion. ( 27034199 )
2016

Variations for Central Retinal Vein Occlusion

Expression for Central Retinal Vein Occlusion

Search GEO for disease gene expression data for Central Retinal Vein Occlusion.

Pathways for Central Retinal Vein Occlusion

GO Terms for Central Retinal Vein Occlusion

Sources for Central Retinal Vein Occlusion

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....